Advisory board · Dr. Liam Quinn

10 Apr 2026 · In person · Dr. Liam Quinn, Institut Curie · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0164—

Capture insight from this engagement

Location: Institut Curie
Therapeutic area: Nephrology
Country: France
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Treatment burden and fatigue
eGFR slope interpretation
APRIL pathway mechanism

Scientific content used

APRIL-IgAN Phase III topline

Questions raised

How does proteinuria reduction at 9 months translate to eGFR benefit?
Is there any data on APRIL inhibition in FSGS?

Notes

Advisory board with academic nephrologist at Institut Curie. Discussed treatment burden and fatigue, egfr slope interpretation, april pathway mechanism.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0164

Audit history (0)

All create, update and approval events for this record

No audit events in sample data